Wilsey Asset Management Inc. Boosts Stock Holdings in Pfizer Inc. $PFE

Wilsey Asset Management Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,195,395 shares of the biopharmaceutical company’s stock after buying an additional 91,852 shares during the quarter. Pfizer makes up approximately 4.6% of Wilsey Asset Management Inc.’s investment portfolio, making the stock its 13th largest holding. Wilsey Asset Management Inc.’s holdings in Pfizer were worth $29,765,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the 3rd quarter valued at $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer in the second quarter worth $30,000. Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth $32,000. Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer in the second quarter valued at $33,000. Finally, True Wealth Design LLC lifted its holdings in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.98 on Friday. The stock has a market cap of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47. The stock’s 50-day moving average is $26.68 and its 200 day moving average is $25.60. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the business posted $0.63 EPS. The business’s quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the stock a “positive” rating in a report on Tuesday. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Finally, HSBC upped their price target on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.14.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.